Kristine D. Duffy - 05 Nov 2024 Form 3 Insider Report for ARROW FINANCIAL CORP (AROW)

Role
Director
Signature
Penko Ivanov, Attorney in Fact
Issuer symbol
AROW
Transactions as of
05 Nov 2024
Net transactions value
$0
Form type
3
Filing time
08 Nov 2024, 13:33:52 UTC
Next filing
29 Jan 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding AROW Common Stock 3,304 05 Nov 2024 Direct
holding AROW Common Stock 790 05 Nov 2024 Held by spouse F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding AROW Director Stock Option (Right to Buy) 05 Nov 2024 Common Stock 546 $27.04 Direct F2
holding AROW Director Stock Option (Right to Buy) 05 Nov 2024 Common Stock 530 $33.78 Direct F3
holding AROW Director Stock Option (Right to Buy) 05 Nov 2024 Common Stock 515 $31.47 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for any purpose.
F2 The options vest 25% per year in equal installments, starting one year from the grant date. One quarter of the options vested and became exercisable on each of January 27, 2022; January 27, 2023; and January 27, 2024; one quarter will vest and become exercisable on January 27, 2025.
F3 The options vest 25% per year in equal installments, starting one year from the grant date. One quarter of the options vested and became exercisable on each of January 26, 2023, and January 26, 2024; one quarter will vest and become exercisable on each of January 26, 2025, and January 26, 2026.
F4 The options vest 25% per year in equal installments, starting one year from the grant date. One quarter of the options vested and became exercisable on February 1, 2024; one quarter will vest and become exercisable on each of February 1, 2025; February 1, 2026; and February 1, 2027.